Lytix Biopharma is pleased to announce that the 1st cohort LTX-315 (3mg) monotherapy in patients with metastatic solid tumours (any) has completed. Three patients received all planned injections of LTX-315 over 3 weeks with no clinically significant LTX-315 related adverse events or dose-limiting toxicities observed.

Andrew Saunders, CMO of Lytix Biopharma, commented:

‘We are very pleased that LTX-315 appears safe and feasible and eagerly await completion of all planned dose cohorts in the coming months.”